Title for MeetingAbstracts
Alphabetical listing of titles
HIV protease inhibitor HOE/BAY 793. Part 2: Virological characterisation.
HIV protease inhibitor HOE/BAY 793. Part 3: In vitro efficacy in infected monocytes/macrophages.
HIV protease inhibitor HOE/BAY 793. Part 4: Long term treatment in persistently HIV-1 infected cells.
HIV protease inhibitor lipid prodrug exhibits greatly prolonged plasma residence time in vivo.
HIV protease inhibitor RO 31-8959: absence of immunoregulatory effects.
HIV protease inhibitor therapy increases hepatic lipoprotein production via stabilization of activated sterol regulatory element-binding protein-1 (SREBP-1) in the nucleus.
HIV protease inhibitor therapy is associated with increased time to relapse and death in AIDS patients with cytomegalovirus retinitis.
HIV protease inhibitors block adipogenesis and increase lipolysis in vitro.
HIV protease inhibitors block angiogenesis and promote regression of Kaposi's sarcoma.
HIV protease inhibitors do not prevent cell death during single-cycle HIV infection of CEM-ss cells in vitro.
HIV protease inhibitors have a direct anti-Candida effect by inhibition of Candida aspartyl proteinase.
HIV Protease Inhibitors Impair Endothelial Nitric Oxide Synthase-mediated Vasodilation in Response to Acetylcholine and Bradykinin.
HIV Protease Inhibitors Increase Adiponectin Levels in HIV-negative Men Independent of Induction of Insulin Resistance.
HIV Protease Inhibitors-Induced Insulin Resistance: Agent and Cell-Type Specificity.
HIV protease inhibitors: action to efficacy.
HIV protease inhibitors: plasma protein binding and pharmacodynamics.
HIV protease inhibitors: structure-activity relationship of water-soluble peptidomimetic compounds with potent antiviral activity.
HIV protease sequences selected during ZDV-ddC-ritonavir triple combination.
HIV protection strategies of heterosexual men: the impact of somatic culture.
HIV protection: high vs. low risk sexual behavior in a seronegative cohort.
HIV protein specific cytotoxic effector cells are expanded in vitro by gag, env or nef specific stimulation.
HIV proteinase mutant in cell culture.
HIV proteinase triggered complement activation?
HIV proteins synthetic fragments: molecular and immunological aspects of HIV infection (a review).
HIV Proteomics Resource: combining HIV-1 protein data with bioinformatics tools.
HIV proviral DNA in peripheral blood mononuclear cells (PBM) in patients on long term therapy with dideoxyinosine (ddI), as assessed by quantitative polymerase chain reaction (PCR).
HIV provirus detection by PCR in seronegative drug addicts. The NISDA Study Group.
HIV provirus load in dendritic cell-enriched cell preparations.
HIV psychological and social care services; an evaluation.
HIV quality improvement monitoring improves delivery of ambulatory HIV clinical care.